drugset / Trial / NCT06758947
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF
RandomizedParallel-groupTriple-blindTreatment
Summary
Systemic sclerosis (SSc) is a systemic autoimmune disease with heterogeneous clinical presentation and prognosis. JAK inhibitors reduced cutaneous and pulmonary fibrosis in mice models of SSc. Clinical data regarding the efficacy and safety of JAK inhibitors in SSc patients are scarce
Timeline
- Start
- 2023-01-15
- Primary completion
- 2024-06-15
- Completion
- 2024-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MMF | Unknown | 2 g | Oral |
| Subject | Upadacitinib | Small molecule | 15 mg | Oral |